
This study aims to evaluate the efficacy and safety of DH in type 1 diabetes. 17 randomised crossover trials (438 participants) were included. DH seemed to have a comparable effect on target time compared to SH, but increased time in the target range compared with SAP/CSII and PLGS. DH slightly reduced time in hypoglycemia but could increase the risk of gastrointestinal symptoms compared with SH.
Like
Save
Share